Life Science Platform Promotes True Scientific Collaboration

SyynX Solutions GmbHCollexis (OTCBB: CLXS), a leading developer of high-definition search and discovery software, and their German partner, SyynX Solutions, announced they will preview a new life sciences social networking site to representatives from global book publishing and multimedia companies at the Frankfurt Book Fair in Frankfurt, Germany. This online community represents the next generation in social networks. The comprehensive system of pre-populated expert profiles, coupled with the ability to analyze all associated professional connections within the network, allows scientists and researchers across multiple organizations to share data and collaborate in ways never before considered.

Over the next few weeks, a controlled group of research thought leaders are testing the site for a public launch slated for January, when the site's name and web address will be formally released to the public. However, Frankfurt Book Fair attendees can gain access to the site at the companies' joint booth, number 417 in Hall 4.2, at any time during the conference.

Designed to promote collaborative research and development in advancing medical science, the site is the first social networking application to incorporate pre-generated expert profiles of over 1.4 million biomedical experts from more than 150 countries. It currently houses approximately 12 million pre-established network connections, automatically generated from over six million scientific publications from 6,500 journals. Contrary to the first generation social networks like Facebook and LinkedIn, this life science open platform goes to the next level and reflects the real-life activity network of the experts worldwide.

"Social networking isn't just for teenagers. There are a growing number of academics who are finding that online communities are the perfect way to share, collaborate and discuss their work," said Bill Kirkland, Collexis CEO. "But until now, an efficient way to coordinate the abundance of available digital information did not exist. The technology behind our site now makes it possible for researchers to collaborate in a way not previously possible."

"When a researcher logs into the site, available at no-charge, they will immediately see a robust synopsis of their publications, interests and network," added Kirkland. "The depth of this information, encompassing almost every published researcher in the biomedical sciences field worldwide, is what makes the site incredibly powerful. It also serves as a definitive source to identify relationships to others within the community, either by topic or geography."

The social networking site is based on Collexis' proprietary Fingerprint technology, a valuable research tool already employed by organizations such as: Johns Hopkins, The Mayo Clinic, Harvard University and The National Institute of Health.

"Taking the Collexis technology, which has become the platform of choice for leading biomedical companies, and combining it with a free social network application was really the next logical step," said Christian Herzog, MD, CEO of SyynX Solutions. "Thanks to the genius of Martin Schmidt, our chief technology officer, in collaboration with the Collexis leadership, the research community will now be able to instantaneously identify relevant expertise in a specific research area and start collaborating directly. Plus, we see the next generations of this platform expanding beyond biomedical research and into larger, global R&D development efforts."

About Collexis Holdings, Inc.
Collexis Holdings, Inc., a leading developer of High Definition Search and Discovery software since 1999, is headquartered in Columbia, South Carolina (USA) with two subsidiaries; Collexis Inc. in Columbia, South Carolina, USA and Collexis, B.V. in Geldermalsen, The Netherlands. Collexis proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, websites, e-mails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis shares of common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, please visit www.collexis.com.

About SyynX Solutions GmbH
SyynX Solutions GmbH is a German software company which focuses on text mining based applications for the areas of life science and health care. Collexis and SyynX are already co-operating closely since almost ten years on the technical and commercial level. The SyynX applications based on the Collexis fingerprint technology are used by customers like universities, pharmaceutical and biotech companies around the world. The text mining applications like the SyynX Knowledge Dashboard helps the user to analyze large text corpora without applying standard search approaches and provides him automatically with expert profiles, trends and knowledge discovery routines. For more information please visit www.syynx.de.

Most Popular Now

Swissmedic begins rolling review of Moderna's mRNA…

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for...

Moderna's COVID-19 vaccine candidate meets its pri…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for...

Pfizer and BioNTech conclude Phase 3 study of COV…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based...

Pfizer and BioNTech to submit Emergency Use Author…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authori...

Phase 2 trial of Oxford COVID-19 vaccine in health…

The UK's vaccine against SARS-CoV-2 shows similar safety and immunogenicity results in healthy older adults (aged 56 years and over) to those seen in adults aged 18-55 ye...

Lilly's neutralizing antibody bamlanivimab (LY-CoV…

The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for Eli Lilly and Company's (NYSE: LLY) investigational neutralizing antibody bamlan...

Chinese vaccine candidate based on inactivated SAR…

Results from an early-phase randomised clinical trial of a Chinese vaccine candidate based on the inactivated whole SARS-CoV-2 virus (CoronaVac) are published in The Lanc...

Medicago and GSK announce start of Phase 2/3 clini…

Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK have announced the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate f...

European Commission approves contract with BioNTec…

Today, the European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses ...

Pre-existing coronavirus antibodies could help pro…

Researchers at the Francis Crick Institute and University College London have found that some antibodies, created by the immune system during infection with common cold c...

Fluvoxamine may prevent serious illness in COVID-1…

In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Me...

The Sputnik V COVID-19 vaccine efficacy amounted t…

The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Rus...